Navigation Links
Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012

TARRYTOWN, N.Y., Jan. 26, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2011 financial and operating results on Thursday, February 16, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EST that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at Information:   

 Manisha Narasimhan, Ph.D.

Peter DworkinInvestor Relations

Corporate Communications914-847-5126 

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
2. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
3. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
4. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
5. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
6. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
7. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
8. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
9. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
10. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
11. Regeneron Reports Second Quarter 2011 Financial and Operating Results
Post Your Comments:
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ...
(Date:12/1/2015)... New York , December 1, 2015 ... Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives, Male ... Implants, Contraceptive Vaginal Rings, Contraceptive Diaphragms, Contraceptive ... Industry Analysis, Size, Share, Growth, Trends and ... released by Transparency Market Research (TMR).The report ...
(Date:12/1/2015)... SAN DIEGO , Dec. 1, 2015   ... oncology drug development company, announces it has filed an ... and Drug Administration (FDA) for the Company,s lead fully ... Subject to FDA acceptance, MabVax plans to initiate the ... --> --> The planned ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... The North American Meat Institute today unveiled ... poultry play in a healthy, balanced diet. , includes a section about ... their “meat IQ,” a section offering straight talk on controversies, information on buying ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... oncology and hematology continuing medical education (CME), today announced that the first annual ... Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers are ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... professionals who believe that with innovative technologies and under the right circumstances, these ... get the benefit of a dual-approach to his or her therapeutic sessions, as ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
Breaking Medicine News(10 mins):